Beam Therapeutics (BEAM) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Vericel (VCEL) has outperformed Beam Therapeutics (BEAM) over the past year, gaining 23.0% versus a loss of 1.4%. Over five years, VCEL leads with a -19.8% price change compared with -73.4% for BEAM. Beam Therapeutics is the larger company by market cap ($2.56 billion vs $2.09 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BEAM | VCEL |
|---|---|---|
| Share price | $24.77 | $40.74 |
| Market cap | $2.56B | $2.09B |
| 1-day change | -1.82% | +1.72% |
| YTD return | -10.64% | +13.14% |
| 1-year return | -1.43% | +23.04% |
| 5-year return | -73.41% | -19.79% |
| P/E ratio (TTM) | — | 86.68 |
| Forward P/E | — | 48.16 |
| EPS (TTM) | $-0.68 | $0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.26 | $49.32 |
| 52-week low | $20.23 | $28.95 |
| Distance from 52-week high | -35.26% | -17.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +110.54% | +48.67% |
| Average volume | 1.94M | 503.13K |
| Shares outstanding | 103.29M | 51.21M |
| Employees | 540 | 398 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VCEL has outperformed BEAM by 24.5 percentage points over the past year.
About Beam Therapeutics
BEAM stock →Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 540 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 398 employees
BEAM vs VCEL FAQ
Which is bigger, Beam Therapeutics or Vericel?
Beam Therapeutics (BEAM) is larger, with a market capitalization of $2.56B compared with $2.09B for Vericel (VCEL).
Which stock has performed better over the past year, BEAM or VCEL?
VCEL returned +23.04% over the past 12 months, compared with -1.43% for BEAM (price return, excluding dividends). Past performance does not predict future results.
Are Beam Therapeutics and Vericel in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.